Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens
Predictive Oncology (Nasdaq: POAI) has announced two private placement transactions totaling $344.4 million to implement a digital asset treasury strategy focused on Aethir (ATH) tokens. The transactions include a $51.7 million Cash PIPE offering approximately 66.7 million common stock shares and a $292.7 million Crypto PIPE offering pre-funded warrants for 223.6 million shares.
The company will partner with Aethir, which operates one of the world's largest decentralized GPU networks, providing AI infrastructure with 40-80% cost savings compared to traditional providers. The network spans 435,000 GPU containers across 93 countries. Notably, Shawn Matthews, former CEO of Cantor Fitzgerald, will join the Board upon closing, expected around October 2, 2025.
The company will also undergo a 1-for-15 reverse stock split effective September 30, 2025. For each ATH token purchased, the DCI Foundation will grant an additional 20% in tokens to POAI.
Predictive Oncology (Nasdaq: POAI) ha annunciato due operazioni di collocamento privato per un totale di 344,4 milioni di dollari volte a implementare una strategia di tesoreria di asset digitali focalizzata sui token Aethir (ATH). Le operazioni includono un'offerta Cash PIPE da 51,7 milioni di dollari che comprende circa 66,7 milioni di azioni ordinarie e un'offerta Crypto PIPE da 292,7 milioni di dollari con warrant prefinanziati per 223,6 milioni di azioni.
La società collaborerà con Aethir, che gestisce una delle più grandi reti GPU decentralizzate al mondo, fornendo infrastrutture AI con risparmi sui costi tra il 40% e l'80% rispetto ai fornitori tradizionali. La rete comprende 435.000 contenitori GPU in 93 paesi. In particolare, Shawn Matthews, ex CEO di Cantor Fitzgerald, entrerà nel Comitato dopo la chiusura, prevista verso il 2 ottobre 2025.
La società subirà anche uno split azionario inverso 1-for-15 efficacious dal 30 settembre 2025. Per ogni token ATH acquistato, la DCI Foundation elargirà un ulteriore 20% in token a POAI.
Predictive Oncology (Nasdaq: POAI) ha anunciado dos operaciones de colocación privada por un total de 344,4 millones de dólares para implementar una estrategia de tesorería de activos digitales centrada en los tokens Aethir (ATH). Las transacciones incluyen una oferta Cash PIPE por 51,7 millones de dólares que comprende aproximadamente 66,7 millones de acciones comunes y una oferta Crypto PIPE por 292,7 millones de dólares con warrants prefinanciados para 223,6 millones de acciones.
La empresa se asociará con Aethir, que opera una de las redes GPU descentralizadas más grandes del mundo, proporcionando infraestructura de IA con ahorros de costos del 40-80% frente a proveedores tradicionales. La red abarca 435.000 contenedores de GPU en 93 países. Notablemente, Shawn Matthews, ex CEO de Cantor Fitzgerald, se unirá a la Junta directiva tras el cierre, previsto alrededor del 2 de octubre de 2025.
La compañía también se someterá a un split inverso de acciones de 1 por 15 con efecto el 30 de septiembre de 2025. Por cada token ATH adquirido, la Fundación DCI otorgará un adicional del 20% en tokens a POAI.
Predictive Oncology (나스닥: POAI)가 ATH 토큰에 집중된 디지털 자산 금고 전략을 실행하기 위해 총 3억 4,440만 달러의 두 차례 비공개 배정 거래를 발표했습니다. 거래에는 약 6,670만 주의 보통주를 포함하는 현금 PIPE와 223.6백만 주의 주식에 대한 사전 지급 워런트가 포함된 암호 PIPE가 포함됩니다.
회사는 전 세계에서 가장 큰 탈중앙화 GPU 네트워크 중 하나를 운영하는 Aethir과 파트너십을 맺습니다. 전통 공급자에 비해 비용이 40-80% 절감되는 AI 인프라를 제공합니다. 네트워크는 93개국에 걸쳐 435,000개의 GPU 컨테이너로 구성되어 있습니다. 특히 Cantor Fitzgerald의 전 CEO Shawn Matthews가 2025년 10월 2일경으로 예상되는 마감 시점에 이사회에 합류합니다.
또한 회사는 2025년 9월 30일부터 적용되는 1대 15의 역주식 분할을 실시합니다. ATH 토큰이 구매될 때마다 DCI 재단은 POAI에 추가로 20%의 토큰을 부여합니다.
Predictive Oncology (Nasdaq: POAI) a annoncé deux transactions de placement privé pour un total de 344,4 millions de dollars afin de mettre en œuvre une stratégie de trésorerie d'actifs numériques axée sur les jetons Aethir (ATH). Les transactions comprennent une offre Cash PIPE de 51,7 millions de dollars représentant environ 66,7 millions d'actions ordinaires et une offre Crypto PIPE de 292,7 millions de dollars avec des warrants préfinancés pour 223,6 millions d'actions.
La société s'associera à Aethir, qui exploite l'une des plus grandes réseaux GPU décentralisés au monde, fournissant une infrastructure IA avec des économies de coûts de 40 à 80% comparé aux fournisseurs traditionnels. Le réseau compte 435 000 conteneurs GPU dans 93 pays. Fait notable, Shawn Matthews, ancien PDG de Cantor Fitzgerald, rejoindra le Conseil après la clôture, prévue vers le 2 octobre 2025.
La société procèdera également à une répartition inversée d'actions 1 pour 15 effective le 30 septembre 2025. Pour chaque jeton ATH acheté, la Fondation DCI accordera un supplément de 20% en jetons à POAI.
Predictive Oncology (Nasdaq: POAI) hat zwei private Platzierungstransaktionen im Gesamtwert von 344,4 Mio. USD angekündigt, um eine Digital-Asset-Treasury-Strategie mit ATH-Token zu implementieren. Die Transaktionen umfassen ein Cash-PIPE im Wert von 51,7 Mio. USD mit ca. 66,7 Mio. Stammaktien und ein Crypto-PIPE im Wert von 292,7 Mio. USD mit vorfinanzierten Warrants für 223,6 Mio. Aktien.
Das Unternehmen wird mit Aethir zusammenarbeiten, das eines der weltweit größten dezentralen GPU-Netzwerke betreibt und AI-Infrastruktur mit 40-80% Kosteneinsparungen gegenüber traditionellen Anbietern bietet. Das Netz umfasst 435.000 GPU-Container in 93 Ländern. Bemerkenswert ist, dass Shawn Matthews, ehemaliger CEO von Cantor Fitzgerald, nach Abschluss der Transaktionen dem Vorstand beitreten wird, voraussichtlich um den 2. Oktober 2025.
Das Unternehmen wird außerdem eine 1-für-15 Reverse-Stock-Split wirksam am 30. September 2025 durchführen. Für jeden ATH-Token, der gekauft wird, wird die DCI-Stiftung POAI zusätzliche 20% an Tokens gewähren.
Predictive Oncology (ناسداك: POAI) أعلنت عن عمليتي تخصيص خاصتين بمجموع 344.4 مليون دولار لتنفيذ استراتيجية الخزينة للأصول الرقمية المركزة على رموز Aethir (ATH). تتضمن المعاملات عرضاً Cash PIPE بقيمة 51.7 مليون دولار يتألف من نحو 66.7 مليون سهم عادي وعرضاً Crypto PIPE بقيمة 292.7 مليون دولار مع مذكرات منح مبدئية لـ 223.6 مليون سهم.
ستتعاون الشركة مع Aethir، التي تشغل إحدى أكبر الشبكات GPU اللامركزية في العالم، مقدمة بنية تحتية للذكاء الاصطناعي مع وفورات في التكلفة تتراوح بين 40-80% مقارنة بمزودي الخدمات التقليديين. الشبكة تمتد إلى 435,000 حاوية GPU في 93 دولة. ومن الجدير بالذكر أن شون ماثيوز، الرئيس التنفيذي السابق لشركة Cantor Fitzgerald، سينضم إلى المجلس بعد الإغلاق المرتقب في حوالي 2 أكتوبر 2025.
ستقوم الشركة أيضاً بإجراء تجزئة عكسية للسهم بمعدل 1 مقابل 15 اعتباراً من 30 سبتمبر 2025. مقابل كل رمز ATH يتم شراءه، ستمنح مؤسسة DCI POAI إضافة 20% من الرموز.
Predictive Oncology (纳斯达克: POAI)宣布两笔私募交易,总额为3.444亿美元,以实施以 ATH(Aethir)代币为核心的数字资产金库策略。交易包括一项 现金 PIPE 5170万美元,约包含 6670万股普通股,以及一项 加密 PIPE 2.927亿美元,附带对 2236万股的预先发行认股权证。
公司将与 Aethir 合作,后者运营全球最大的去中心化 GPU 网络之一,提供 AI 基础设施,相较传统供应商实现 40-80% 的成本节省。网络覆盖 93个国家的435,000个 GPU 容器。值得注意的是,Shawn Matthews,前 Cantor Fitzgerald 的 CEO,将在收盘时加入董事会,预计于 2025 年 10 月 2 日左右。
公司还将于 2025 年 9 月 30 日生效实施 1 对 15 的股票反向分割。每购买一个 ATH 代币,DCI 基金会将向 POAI 额外发放 20% 的代币。
- Substantial capital raise of $344.4 million through combined PIPE transactions
- Strategic partnership with Aethir provides access to significant GPU infrastructure with 40-80% cost savings
- Additional 20% bonus ATH tokens granted for each token purchased
- Former Cantor Fitzgerald CEO Shawn Matthews joining Board of Directors
- Establishment of world's first Strategic Compute Reserve through ATH holdings
- Significant dilution through issuance of approximately 290.3 million new shares/warrants
- High-risk exposure to volatile cryptocurrency assets through ATH tokens
- Implementation of 1-for-15 reverse stock split indicates potential listing compliance issues
- Substantial pivot from core oncology business model introduces execution risk
Insights
POAI's $344M private placements for digital asset strategy represents significant pivot while diluting shareholders substantially.
Predictive Oncology's announced $344.4 million private placements represent a massive capital raise relative to the company's size and a dramatic strategic shift. The company is raising funds through two separate PIPE transactions: $51.7 million in cash and $292.7 million in notional value ($173.3 million discounted) of Aethir tokens.
This move represents a significant pivot from POAI's core oncology AI business toward becoming what they're calling a "Strategic Compute Reserve" centered around ATH tokens from Aethir's decentralized GPU network. The scale of this transaction suggests a fundamental transformation rather than a complementary strategy.
Investors should note the enormous potential dilution. The deal includes approximately 66.7 million new common shares plus pre-funded warrants for an additional 223.6 million shares. This represents substantial dilution for existing shareholders, especially considering POAI's relatively small market capitalization prior to this announcement.
Adding complexity, POAI announced a 1-for-15 reverse stock split effective September 30, 2025. This typically indicates a company struggling to maintain minimum share price requirements for continued Nasdaq listing.
The strategic partnership with Aethir positions POAI to potentially benefit from reduced AI infrastructure costs (claimed 40-80% savings), which could theoretically support their original oncology AI business. However, the primary focus appears to be establishing a digital asset treasury strategy centered on ATH tokens, which introduces significant cryptocurrency exposure and volatility to what was previously a biotech AI company.
The appointment of Shawn Matthews (former Cantor Fitzgerald CEO) to the board adds financial markets expertise but further signals this dramatic shift away from the company's original biomedical focus.
Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements
Predictive Oncology continues to execute on its artificial intelligence and machine learning business to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide
PITTSBURGH, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (“Predictive Oncology” or the “Company”) (Nasdaq: POAI) today announced the pricing of two private placement transactions to support its adoption of a digital asset treasury strategy under which the principal holding will be ATH, the native utility token of the Aethir ecosystem.
Transaction Overview
The Company to raise an aggregate of approximately
The Company intends to use the in-kind contribution of ATH to fund the Company’s digital asset treasury strategy and to use the remaining net proceeds from the PIPEs primarily to fund the acquisition of ATH in the open market in further support thereof, as well as for working capital and general corporate purposes.
DNA Holdings Venture, Inc. will serve as the Company’s strategic advisor and consultant for the Company’s digital asset treasury.
Aethir operates one of the world’s largest decentralized GPU networks, offering enterprise-grade AI infrastructure with approximately 40–
To expand this reach, the Company’s digital asset treasury will manage ATH tokens, leveraging Aethir’s flywheel model by facilitating rapid deployment and monetization of compute resources across Web2 and Web3 enterprise verticals. ATH tokens provide the utility, rewards, and access to high-end GPU compute resources. Compute providers stake ATH as collateral, ensuring service level adherence and enabling rapid deployment.
For each ATH token purchased by the Company on the open market, whether through a centralized exchange or a decentralized exchange operating on the Ethereum Network, the DCI Foundation will grant to the Company an additional
“Our partnership with Aethir represents a seminal event for Predictive Oncology and we believe it creates an outstanding opportunity for the Company and our shareholders to solidify and expand our core business while embarking upon an incremental growth opportunity through our digital asset treasury strategy,” commented Raymond Vennare, Chief Executive Officer and Chairman of the Board of Predictive Oncology.
“With the planned adoption of the Company’s digital asset strategy, we will be able to establish the world’s first Strategic Compute Reserve. The Company will act not just as a digital asset treasury, but through its planned holdings of ATH, it will be able to function as an operator on the Aethir ecosystem that we believe will strengthen Aethir’s ability to provide the global infrastructure layer for the future of AI,” said Dan Wang, Co-Founder and CEO of Aethir.
Advisors
DNA Holdings Venture Inc. is acting as the strategic advisor and an investor in the Cash PIPE.
H.C. Wainwright & Co. is acting as the exclusive placement agent in connection with the PIPEs.
DLA Piper LLP (US) is serving as counsel to the Company.
Shepphard, Mullin, Richter & Hampton LLP, is serving as counsel to DNA Holdings Venture, Inc., the Company’s strategic advisor.
Disclaimer
The offer and sale of the foregoing securities in the PIPEs were made in a private placement in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, and applicable state securities laws. Accordingly, the securities offered in the PIPEs may not be re-offered or re-sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. Concurrently with the execution of the securities purchase agreements for the PIPEs, the Company and the investors entered into a registration rights agreement pursuant to which the Company agreed to file one or more registration statements with the Securities and Exchange Commission registering the resale of the securities to be issued or issuable in connection with the PIPEs.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
The information provided in this press release is intended for informational purposes only and does not constitute investment advice, endorsement, analysis, or recommendations with respect to any financial instruments, investments, or issuers. Investment in cryptocurrency and DeFi projects involves substantial risk, including the risk of complete loss. This press release does not take into account the investment objectives, financial situation, or specific needs of any particular person and each individual is urged to consult their legal and financial advisors before making any investment decisions.
On September 19, 2025, the Company’s stockholders approved a one-for-fifteen (1-for-15) reverse stock split of the Company’s common stock which will become effective at 12:01 a.m. on Tuesday, September 30, 2025. All share and price per share information included in this press release is presented on a pre-split basis and the exercise price of
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with
The Company will initiate a digital asset treasury strategy focused on accumulating ATH, the native utility token of the Aethir ecosystem.
About Aethir
Aethir is a leading AI decentralized physical infrastructure network (“DePIN”) developed by DCI Foundation, a Panama foundation company which provides graphics processing units (“GPUs”) as-a-Service at enterprise scale for applications including artificial intelligence computation, gaming and cloud workloads. Aethir’s mission is to democratize access to AI infrastructure through its globally distributed network. Due in part to the decentralized nature of the Aethir network, Aethir can facilitate the provision of GPU compute power at a significant discount to established centralized GPU compute providers, such as AWS and Google Cloud. ATH is a utility token used for GPU rentals, staking, validation and the provision of ecosystem rewards on the Aethir network. ATH functions as a proxy for a unit of GPU compute power, and serves as a medium of exchange and unit of incentives for participants in the Aethir network. Participants in the Aethir network can generate yield or other rewards by staking or lending ATH or by otherwise serving as a source of ATH liquidity.
Forward Looking Statements
This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. This press release also includes express and implied forward-looking statements regarding the Company’s current expectations, estimates, opinions and beliefs that are not historical facts. Such forward-looking statements may be identified by words such as “believes,” “expects,” “endeavors,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “should” and “objective” and the negative and variations of such words and similar words. These statements are made on the basis of current knowledge and, by their nature, involve numerous assumptions and uncertainties. Nothing set forth herein should be regarded as a representation, warranty or prediction that we will achieve or are likely to achieve any particular future result. Actual results may differ materially from those indicated in the forward-looking statements because the realization of those results is subject to many risks and uncertainties, including the risk that the proposed private placements and the transactions described herein may not be completed in a timely manner or at all, the failure to realize the anticipated benefits of the private placement and related transactions, including the Company’s proposed digital asset treasury strategy, economic conditions, fluctuations in the market price of ATH and other digital assets, the impact on the Company’s business of the evolving regulatory environment, the ability of the Company to execute on its digital asset treasury strategy and implications for shareholders and for the Company’s core business, the ability of the Aethir ecosystem to perform in a manner consistent with projections, receipt of shareholder approval for the exercise of the pre-funded warrants issued in connection with the Crypto PIPE and related matters, market and other conditions, as well as other factors. Forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertake no duty to update such information except as required under applicable law.
Investor Relations Contact:
Michael Moyer
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
